167 related articles for article (PubMed ID: 17234210)
21. Effect of sodium chloride concentration on fluid-phase assembly and stability of the C3 convertase of the classical pathway of the complement system.
Maeda S; Nagasawa S
Biochem J; 1990 Nov; 271(3):749-54. PubMed ID: 2244876
[TBL] [Abstract][Full Text] [Related]
22. Stringent regulation of complement lectin pathway C3/C5 convertase by C4b-binding protein (C4BP).
Rawal N; Rajagopalan R; Salvi VP
Mol Immunol; 2009 Sep; 46(15):2902-10. PubMed ID: 19660812
[TBL] [Abstract][Full Text] [Related]
23. The effects of iodine and thiol-blocking reagents on complement component C2 and on the assembly of the classical-pathway C3 convertase.
Kerr MA; Parkes C
Biochem J; 1984 Apr; 219(2):391-9. PubMed ID: 6611150
[TBL] [Abstract][Full Text] [Related]
24. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor.
Rooijakkers SH; Wu J; Ruyken M; van Domselaar R; Planken KL; Tzekou A; Ricklin D; Lambris JD; Janssen BJ; van Strijp JA; Gros P
Nat Immunol; 2009 Jul; 10(7):721-7. PubMed ID: 19503103
[TBL] [Abstract][Full Text] [Related]
25. Structure/function of C5 convertases of complement.
Rawal N; Pangburn MK
Int Immunopharmacol; 2001 Mar; 1(3):415-22. PubMed ID: 11367526
[TBL] [Abstract][Full Text] [Related]
26. Mouse complement component C4 is devoid of classical pathway C5 convertase subunit activity.
Ebanks RO; Isenman DE
Mol Immunol; 1996 Feb; 33(3):297-309. PubMed ID: 8649451
[TBL] [Abstract][Full Text] [Related]
27. The role of properdin in the assembly of the alternative pathway C3 convertases of complement.
Hourcade DE
J Biol Chem; 2006 Jan; 281(4):2128-32. PubMed ID: 16301317
[TBL] [Abstract][Full Text] [Related]
28. The purification and properties of the second component of guinea-pig complement.
Kerr MA; Gagnon J
Biochem J; 1982 Jul; 205(1):59-67. PubMed ID: 6922702
[TBL] [Abstract][Full Text] [Related]
29. Purification and characterization of the C3 convertase of the classical pathway of human complement system by size exclusion high-performance liquid chromatography.
Nagasawa S; Kobayashi C; Maki-Suzuki T; Yamashita N; Koyama J
J Biochem; 1985 Feb; 97(2):493-9. PubMed ID: 3874204
[TBL] [Abstract][Full Text] [Related]
30. Regulation and deregulation of the fluid-phase classical pathway C3 convertase.
Gigli I; Sorvillo J; Halbwachs-Mecarelli L
J Immunol; 1985 Jul; 135(1):440-4. PubMed ID: 3158705
[TBL] [Abstract][Full Text] [Related]
31. The crystal structure of cobra venom factor, a cofactor for C3- and C5-convertase CVFBb.
Krishnan V; Ponnuraj K; Xu Y; Macon K; Volanakis JE; Narayana SV
Structure; 2009 Apr; 17(4):611-9. PubMed ID: 19368894
[TBL] [Abstract][Full Text] [Related]
32. Ultrastructure of cobra venom factor-dependent C3/C5 convertase and its zymogen, factor B of human complement.
Smith CA; Vogel CW; Müller-Eberhard HJ
J Biol Chem; 1982 Sep; 257(17):9879-82. PubMed ID: 6921201
[TBL] [Abstract][Full Text] [Related]
33. 3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase.
Torreira E; Tortajada A; Montes T; Rodríguez de Córdoba S; Llorca O
Proc Natl Acad Sci U S A; 2009 Jan; 106(3):882-7. PubMed ID: 19136636
[TBL] [Abstract][Full Text] [Related]
34. Structural Basis for Properdin Oligomerization and Convertase Stimulation in the Human Complement System.
Pedersen DV; Gadeberg TAF; Thomas C; Wang Y; Joram N; Jensen RK; Mazarakis SMM; Revel M; El Sissy C; Petersen SV; Lindorff-Larsen K; Thiel S; Laursen NS; Fremeaux-Bacchi V; Andersen GR
Front Immunol; 2019; 10():2007. PubMed ID: 31507604
[TBL] [Abstract][Full Text] [Related]
35. A Schistosoma protein, Sh-TOR, is a novel inhibitor of complement which binds human C2.
Inal JM; Sim RB
FEBS Lett; 2000 Mar; 470(2):131-4. PubMed ID: 10734221
[TBL] [Abstract][Full Text] [Related]
36. Positively charged amino acids at the interface between alpha-chain CCP1 and CCP2 of C4BP are required for regulation of the classical C3-convertase.
Blom AM; Zadura AF; Villoutreix BO; Dahlbäck B
Mol Immunol; 2000 Jun; 37(8):445-53. PubMed ID: 11090879
[TBL] [Abstract][Full Text] [Related]
37. Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity.
Mannes M; Dopler A; Zolk O; Lang SJ; Halbgebauer R; Höchsmann B; Skerra A; Braun CK; Huber-Lang M; Schrezenmeier H; Schmidt CQ
Blood; 2021 Jan; 137(4):443-455. PubMed ID: 33507296
[TBL] [Abstract][Full Text] [Related]
38. Monoclonal anti-human C4b antibodies: stabilization and inhibition of the classical-pathway C3 convertase.
Ichihara C; Nakamura T; Nagasawa S; Koyama J
Mol Immunol; 1986 Feb; 23(2):151-7. PubMed ID: 2422544
[TBL] [Abstract][Full Text] [Related]
39. Factor B structure provides insights into activation of the central protease of the complement system.
Milder FJ; Gomes L; Schouten A; Janssen BJ; Huizinga EG; Romijn RA; Hemrika W; Roos A; Daha MR; Gros P
Nat Struct Mol Biol; 2007 Mar; 14(3):224-8. PubMed ID: 17310251
[TBL] [Abstract][Full Text] [Related]
40. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
